Research letter
The CONTROL study: A randomized, double-blind vehicle-controlled phase 2b study of novel topical isotretinoin formulation demonstrates improvement in recessive X-linked and autosomal recessive lamellar congenital ichthyosis

https://doi.org/10.1016/j.jaad.2022.07.028Get rights and content
Under a Creative Commons license
open access

Cited by (0)

Funding sources: This work was supported by Timber Pharmaceuticals.

IRB approval status: This study was approved by institutional review boards/independent ethics committees at each center and was conducted according to the International Council for Harmonisation Tripartite Guidelines for Good Clinical Practice and the Declaration of Helsinki principles. All participants provided written informed consent. Legal guardians or parents provided written informed assent for participants <18 years.

Key words: ARCI-LI; congenital ichthyosis; isotretinoin; retinoids; scaling; Visual Index for Ichthyosis Severity; XLRI.

Reprints not available from the authors.